Search the Newsreel

Oppenheimer Adjusts Corteva Price Target to $95 From $89, Maintains Outperform Rating

Oppenheimer has increased its price target for Corteva (CTVA) to $95 from $89, reiterating an Outperform rating on the stock. This adjustment reflects analyst confidence in the agricultural chemicals company. Other recent analyst actions also show upward revisions to Corteva's price targets.

Militia Capital Management LLC Takes $3.50 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Militia Capital Management LLC has initiated a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), purchasing 116,100 shares valued at approximately $3.5 million in the first quarter. This comes as Teva's stock recently fell by 3.7% to $30.19, despite the company reporting quarterly EPS …

Corteva (NYSE:CTVA) Reaches New 12-Month High - Still a Buy?

Corteva (NYSE:CTVA) recently achieved a new 52-week high, trading up to $88.57, reflecting positive analyst sentiment and strong financial performance. The company surpassed earnings expectations with $1.50 EPS and $4.91 billion in revenue, and analysts maintain a "Moderate Buy" consensus with an average price …

Allspring Global Investments Holdings LLC Raises Stock Holdings in Corteva, Inc. $CTVA

Allspring Global Investments Holdings LLC significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by 93.0% during the first quarter, now holding 133,526 shares valued at $11.19 million. Several other hedge funds also modified their positions in Corteva. The article details Corteva's recent financial performance, …

ABN Amro Investment Solutions Sells 93,474 Shares of Corteva, Inc. $CTVA

ABN Amro Investment Solutions significantly reduced its stake in Corteva, Inc. (NYSE:CTVA) by 59.4% in Q1, selling 93,474 shares and retaining 63,821 shares valued at approximately $5.34 million. Despite this sale, Wall Street analysts maintain a positive outlook, with a consensus "Moderate Buy" rating …

Corteva, Inc. (CTVA) Earnings Expected to Grow: Should You Buy?

Corteva (CTVA) Projected to Post Quarterly Earnings on Thursday

Corteva (CTVA) is expected to announce its Q2 2026 earnings on Thursday, July 30th, with analysts projecting $2.23 EPS on $6.593 billion in revenue. The company recently exceeded expectations in its last quarterly report, posting $1.50 EPS against an estimated $1.18, and saw an …

RBC Raises Price Target on Corteva to $103 From $97, Keeps Outperform Rating

RBC Capital Markets has increased its price target for Corteva (NYSE: CTVA) to $103 from $97, while maintaining an Outperform rating on the stock. This revised target suggests a positive outlook for the agricultural science company, with RBC analysts anticipating continued strong performance.

Corteva Inc. stock underperforms Wednesday when compared to competitors despite daily gains

On Wednesday, Corteva Inc. (CTVA) stock saw a 1.83% increase, closing at $88.53. Despite these daily gains, the stock underperformed compared to its competitors, happening on a generally negative trading day where the S&P 500 and Dow Jones Industrial Average both experienced slight declines. …

Will Corteva, Inc. (CTVA) Beat Estimates Again in Its Next Earnings Report?

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Corteva, Inc. (CTVA). This company, which is in the Zacks …

Teva Pharmaceutical Industries (TEVA) Projected to Post Earnings on Wednesday

Teva Pharmaceutical Industries (TEVA) is projected to announce its Q2 2026 earnings before the market opens on Wednesday, July 29th. Analysts anticipate earnings of $0.08 per share on revenues of $4.0473 billion. Despite recent insider selling, Wall Street maintains a "Moderate Buy" rating with …

77,800 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Barometer Capital Management Inc.

Barometer Capital Management Inc. has acquired a new stake of 77,800 shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the first quarter, valued at approximately $2.34 million. This investment makes Teva Pharmaceutical Industries the 28th largest holding for Barometer Capital Management, representing about 1.0% …

Dimensional Fund Advisors LP Acquires 78,994 Shares of Corteva, Inc. $CTVA

Dimensional Fund Advisors LP increased its stake in Corteva, Inc. (NYSE:CTVA) by 1.7%, purchasing 78,994 additional shares and bringing its total holdings to 4.77 million shares valued at approximately $399.4 million. Wall Street analysts maintain a "Moderate Buy" consensus rating for Corteva with an …

Teva Pharmaceutical Industries (TEVA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Teva Pharmaceutical Industries presented a summary of their 43rd Annual J.P. Morgan Healthcare Conference, highlighting significant strides in their strategic transformation. The company has achieved seven consecutive quarters of revenue growth, moving from a debt-burdened generics company to a global biopharmaceutical leader with a …

Hoka Expected to Drive First Quarter Earnings Results for Deckers, Analysts Say

Hoka remains the key growth engine at parent company Deckers Brands, according to Wall Street analysts. "Our topline growth forecast reflects 8.3 percent growth at Hoka, a 5.0 percent increase across Ugg, and a 35.0 percent drop in the Other brands group (primarily Teva)," …

Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Report - Results, Call & Slides

Teva Pharmaceutical Industries Limited (TEVA) exceeded analyst expectations in its Q3 2024 earnings report, with an actual EPS of $0.69 against a consensus of $0.66, and revenue of $4.35 billion, beating the expected $4.14 billion. This represents a 14.14% year-over-year revenue growth. The company's …

Price-Driven Insight from (STVN) for Rule-Based Strategy

This article provides a price-driven insight for Stevanato Group S.p.a. (NASDAQ: STVN) based on AI models from Stock Traders Daily. It highlights near-term weak sentiment, no clear price positioning signal, and compelling upside potential due to a lack of resistance levels. The report also …

Stevanato Group (STVN) Bank of America Global Healthcare Conference 2026 Summary

Stevanato Group (STVN) presented at the Bank of America Global Healthcare Conference 2026, highlighting its long-term customer partnerships due to high switching costs and regulatory integration, driving strong organic growth through high-value solutions like Nexa syringes. The company emphasized its growth drivers in biologics …

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

Stevanato Group S.p.A. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, at 6:30 a.m. EDT. The company will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss the results, with …

Swiss National Bank Buys 941,700 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

The Swiss National Bank increased its stake in Teva Pharmaceutical Industries (NYSE:TEVA) by 28.7% in the first quarter, purchasing an additional 941,700 shares and bringing its total holdings to 4.23 million shares valued at approximately $127.3 million. Wall Street analysts maintain a "Moderate Buy" …

Mediolanum International Funds Ltd Has $6.17 Million Stock Holdings in Corteva, Inc. $CTVA

Mediolanum International Funds Ltd significantly cut its stake in Corteva (NYSE:CTVA) by 48.5% in the first quarter, now holding 74,337 shares valued at $6.17 million. Despite this reduction, other institutional investors increased their positions, and 81.54% of the stock is held by institutional investors. …

184,568 Shares in Corteva, Inc. $CTVA Purchased by SEB Asset Management AB

SEB Asset Management AB has acquired a new stake of 184,568 shares in Corteva, Inc. (NYSE:CTVA) during the first quarter, valued at approximately $15.45 million. Other institutional investors like Harris Associates L P, Norges Bank, and Northwestern Mutual Wealth Management Co. have also significantly …

Corteva, Inc. $CTVA Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. reduced its stake in Corteva (NYSE:CTVA) by 6.2% in the first quarter, selling 18,258 shares. However, other institutional investors like Vanguard Group Inc., State Street Corp, Franklin Resources Inc., Harris Associates L P, and Northern Trust Corp significantly increased …

Stevanato Group schedules Aug. 4 results webcast at 8:30 a.m.

Stevanato Group (STVN) Investor presentation Summary

Stevanato Group (STVN) presented an investor summary highlighting its operational excellence, market leadership, and strong financial performance. The company has a global footprint, a high-value solutions (HVS) portfolio driving significant revenue growth, and is benefiting from secular tailwinds in the biopharma industry. Future guidance …

Piper Sandler reiterates Teva stock rating on vitiligo drug potential

Piper Sandler has reiterated an "Overweight" rating and a $42.00 price target for Teva Pharmaceutical Industries (NYSE:TEVA), citing positive potential from their IL-15-directed antibody, TEV-'408, for vitiligo treatment. A webinar with a dermatologist highlighted enthusiastical views on the drug's mechanism of action and the …

BofA Securities Adjusts Price Target on Corteva to $96 From $90

BofA Securities has revised its price target for Corteva (NYSE: CTVA) shares, increasing it from $90 to $96. The firm maintains a Neutral rating on the agricultural science company's stock.

Is Profitability Improving Across Mission Produce's Segments?

Mission Produce faced profitability challenges in Q2 fiscal 2026 due to an unusual avocado pricing environment but expects improvement as supply normalizes, pricing stabilizes, and contributions from Peru and the Calavo acquisition strengthen its position. The Marketing & Distribution segment showed resilience despite headwinds, …

Stevanato Group S.p.A. $STVN Stock Holdings Lifted by Van Berkom & Associates Inc.

Van Berkom & Associates Inc. significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 2,944.2% in the first quarter, now holding 170,994 shares valued at $2.35 million. This move comes despite the company missing Q1 earnings estimates, though revenue rose 6.6% year-over-year. Analysts …

WCM Investment Management LLC Sells 92,666 Shares of Corteva, Inc. $CTVA

WCM Investment Management LLC reduced its stake in Corteva (NYSE:CTVA) by 1.1% in the first quarter, selling 92,666 shares but still holding a significant position. Despite the sale, institutional ownership of Corteva remains high at 81.54%. The company recently reported strong quarterly earnings, beating …

Sound Shore Management Inc. CT Lowers Position in Teva Pharmaceutical Industries Ltd. $TEVA

Sound Shore Management Inc. CT reduced its stake in Teva Pharmaceutical Industries Ltd. by 9.8% in Q1 2026, though Teva remains its largest holding, accounting for 3.9% of its portfolio. Despite insider selling, analyst sentiment for Teva is generally positive, with a "Moderate Buy" …

Swiss National Bank Boosts Holdings in Corteva, Inc. $CTVA

The Swiss National Bank increased its stake in Corteva, Inc. by 6.7% in the first quarter, bringing its total holdings to over 1.98 million shares valued at $166 million. Several other institutional investors also adjusted their positions in Corteva during the last quarter. Analysts …

KBC Group NV Purchases 771,480 Shares of Corteva, Inc. $CTVA

KBC Group NV has significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by 58.8% in the first quarter, acquiring an additional 771,480 shares and bringing its total holding to over 2 million shares valued at approximately $174.4 million. This move highlights strong institutional interest, …

Hsbc Holdings PLC Has $106.09 Million Stock Position in Corteva, Inc. $CTVA

HSBC Holdings PLC reduced its stake in Corteva by 6.4% in the first quarter, now holding 1.27 million shares valued at approximately $106.1 million. Despite this, Corteva reported strong quarterly earnings, beating expectations with an EPS of $1.50 and revenue of $4.91 billion. Analysts …

Teva stock’s downward trend continues

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has experienced a continuous downward trend in its stock price, with falls on most trading days in July, causing its market cap to drop to $37.3 billion. Despite this, analyst Ori Hershkovitz maintains a "Buy" recommendation …

Roubaix Capital LLC Has $5.30 Million Holdings in Stevanato Group S.p.A. $STVN

Roubaix Capital LLC significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 96.6% in the first quarter, now holding 385,316 shares valued at $5.3 million. Despite Stevanato Group missing Q1 EPS expectations, analysts maintain a constructive outlook, with recent upgrades and an outperform …